Corpus ID: 212487575

Evaluation of Serum Chromogranin A as a Useful Tumor Marker for Diagnosis of Hepatocellular Carcinoma

@inproceedings{Awadallah2011EvaluationOS,
  title={Evaluation of Serum Chromogranin A as a Useful Tumor Marker for Diagnosis of Hepatocellular Carcinoma},
  author={Ahmed Mohamed Awadallah and Hesham Ali Issa and Mohamed Soliman},
  year={2011}
}
Background: In Egypt, HCC was reported to account for about 4.7% of chronic liver disease patients. Approximately 80% of HCCs are associated with cirrhosis, which is regarded as the most important precancerous etiological factor. Chromogranin A is a cellular marker for neuroendocrine tumors. High serum levels of CgA have also been demonstrated in patients with other malignancies including colon, lung, breast and prostate cancer. Objective: To evaluate serum CgA as a marker for HCC. Patients and… Expand

Figures from this paper

Serological tumor markers of hepatocellular carcinoma: a meta-analysis
  • T. Hussein
  • Medicine
  • The International journal of biological markers
  • 2015
TLDR
GPC3, DCP, AFU and VEGF are suitable markers for HCC, and their determination with AFP may prove to be useful in the diagnosis and screening of HCC. Expand
Serum Golgi protein 73 as a sensitive biomarker for early detection of hepatocellular carcinoma among Egyptian patients with hepatitis C virus-related cirrhosis.
TLDR
Serum Golgi protein 73 could be a valuable biomarker and a useful diagnostic tool for the early diagnosis of HCC in cases of hepatitis C virus-related cirrhosis. Expand
Golgi Protein 73 as a Diagnostic Tool for Hepatocellular Carcinoma in Cirrhotic Hepatitis C Patients
TLDR
It was found that serum GP73 was up-regulated in HCC and it would be more accurate and effective tool than serum AFP in discriminating the malignant liver lesion from the chronic hepatitis. Expand
EVALUATION OF SERUM CHROMOGRANIN-A, ALPHA-1-FUCOSIDASE, NITRIC OXIDE AND GLUTATHIONE PEROXIDASE MARKERS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
TLDR
In conclusion, Cg-A, NO, AFU and GPx can be used as potential serologic markers for diagnosis of HCC. Expand
Annexin A2 as a biomarker for hepatocellular carcinoma in Egyptian patients
TLDR
Serum ANXA2 may serve as a biomarker for the early detection of HCC, and a highly significant difference was found between patients with HCC and chronic liver disease as well as controls with regard to serum ANxA2 levels. Expand
MicroRNA-215 as a Diagnostic Marker in Egyptian Patients with Hepatocellular Carcinoma
TLDR
Plasma level of miR-215 may be a promising biomarker in HCC diagnosis if miR -215 combined with AFP can be used as a diagnostic biomarker, for early detection of HCC. Expand
Serum Squamous Cell Carcinoma Antigen Level in Cirrhotic Chronic Hepatitis C Patients With and Without Hepatocellular Carcinoma
TLDR
Combined SCCA and AFP can be used as in diagnosis of HCC and follow up 3 months after therapeutic intervention. Expand
Transient Elastography can Predict the Risk of Hepatocellular Carcinoma in Egyptian Patients with Chronic Hepatitis C
TLDR
FibroScan could be used as a tool for identifying HCV positive patients who are at high risk of developing HCC, and a positive correlation between the liver stiffness and the presence of HCC was showed. Expand
Serum tumor markers in chronic kidney disease: as clinical tool in diagnosis, treatment and prognosis of cancers
TLDR
This literature review points the role of serum tumor markers in screening, diagnosis, and follow-up of cancer patients in chronic kidney disease patients and renal allograft recipients and impact of Chronic kidney disease and kidney transplantation on different serum tumor marker is briefly explored. Expand
Cytokines as important playmakers of experimental hepatocarcinogenesis confounded by diabetes.
TLDR
Co-induction of DM in the course of hepatocarcinogenesis can dramatically influence disease progression through inflammation and retarded apoptosis and the suggested apoptotic and inflammatory markers seem to be beneficial diagnostic tools for HCC and improve the diagnostic performance of AFP. Expand
...
1
2
...

References

SHOWING 1-10 OF 32 REFERENCES
Chromogranin A levels in chronic liver disease and hepatocellular carcinoma.
  • S. Massironi, M. Fraquelli, +6 authors M. Peracchi
  • Medicine
  • Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2009
TLDR
Despite the evidence of higher CgA levels in patients with HCC, this test has low-diagnostic accuracy and its pathophysiological meaning remains unknown, even if it could suggest an endocrine phenotype of HCC. Expand
Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits.
TLDR
When HCC is suspected and alpha-FP is normal or <200 ng/mL, CgA serum values represent a complementary diagnostic tool, unless kidney or heart failure is present. Expand
Elevated serum chromogranin A in patients with hepatocellular carcinoma
TLDR
Elevated serum levels of chromogranin A are present in over onethird of patients with hepatocellular carcinoma, and it is therefore possible that some hepato cellular carcinomas could acquire a neuroendocrine differentiation. Expand
The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis
TLDR
The progressive elevation of alpha fetoprotein ≥7 ng/mL/month in patients with liver cirrhosis is useful for the diagnosis of hepatocellular carcinoma in patients that do not reach αFP levels ≥200 ng/NL and Prospective studies are required to confirm this observation. Expand
Serum tumor markers for detection of hepatocellular carcinoma.
TLDR
Serum alpha fetoprotein mRNA has been shown to correlate with the metastasis and recurrence of HCC, and it may be the most useful marker to prefigure the prognosis. Expand
Hepatocellular carcinoma in Italian patients with cirrhosis.
TLDR
In the West, as in Asia, patients with cirrhosis of the liver are at substantial risk for hepatocellular carcinoma, with a yearly incidence rate of 3 percent, and the screening program did not appreciably increase the rate of detection of potentially curable tumors. Expand
Elevated Plasma Osteopontin Levels in Patients with Hepatocellular Carcinoma
TLDR
Osteopontin expression was found in the malignant hepatocytes and cancer-infiltrating macrophages, not in the noncancerous hepatocytes or Kupffer cells, proposing elevated plasma OPN levels as a potential biomarker for HCC. Expand
Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum.
TLDR
A set of six peptides distinguished with high prediction accuracy HCC from controls in an Egyptian population with a high rate of chronic HCV infection by mass spectrometric analysis of enriched serum. Expand
Recent developments in the first detection of hepatocellular carcinoma.
TLDR
Sensitivity of HCC detection by blood markers is improved by combining various other markers with AFP, and the newer high sensitivity des-gamma-carboxy-prothrombin (DCP) has been found to be useful. Expand
Evaluation of Chromogranin A Expression in Patients with Non-Neuroendocrine Tumours
TLDR
Chromogranin A levels were found to be elevated in approximately 50% of patients with non-neuroendocrine tumours, suggesting a possible role for somatostatin analogues such as octreotide in the treatment of these tumours. Expand
...
1
2
3
4
...